1. Home
  2. HRZN vs PRLD Comparison

HRZN vs PRLD Comparison

Compare HRZN & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Horizon Technology Finance Corporation

HRZN

Horizon Technology Finance Corporation

N/A

Current Price

$3.15

Market Cap

201.3M

Sector

Finance

ML Signal

N/A

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

N/A

Current Price

$3.23

Market Cap

260.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HRZN
PRLD
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.3M
260.2M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
HRZN
PRLD
Price
$3.15
$3.23
Analyst Decision
Hold
Strong Buy
Analyst Count
6
5
Target Price
$4.71
★ $8.80
AVG Volume (30 Days)
★ 570.3K
243.3K
Earning Date
11-05-2026
11-16-2026
Dividend Yield
★ 22.71%
N/A
EPS Growth
★ 62.50
23.21
EPS
N/A
★ N/A
Revenue
N/A
★ $12,140,000.00
Revenue This Year
$0.10
$74.34
Revenue Next Year
$17.78
$85.56
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 73.43
52 Week Low
$2.94
$1.30
52 Week High
$6.78
$6.83

Technical Indicators

Market Signals
Indicator
HRZN
PRLD
Relative Strength Index (RSI) 22.47 34.61
Support Level N/A $2.69
Resistance Level $4.75 $3.32
Average True Range (ATR) 0.21 0.29
MACD -0.06 -0.04
Stochastic Oscillator 19.93 2.53

Price Performance

Historical Comparison
HRZN
PRLD

About HRZN Horizon Technology Finance Corporation

Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: